Search the hub
Showing results for tags 'Medicine - Clinic neurophysiology'.
-
News Article
Brain changes seen after 'mild' covid
Patient Safety Learning posted a news article in News
Catching Covid may cause changes to the brain, a study suggests. Scientists found significant differences in MRI (magnetic resonance imaging) scans before and after infection. Even after a mild infection, the overall size of the brain had shrunk slightly, with less grey matter in the parts related to smell and memory. The researchers do not know whether the changes are permanent but stressed the brain could heal. Lead author Prof Gwenaelle Douaud, from the Wellcome Centre for Integrative Neuroimaging, at the University of Oxford, said: "We were looking at essentially mild infection, so to see that we could really see some differences in their brain and how much their brain had changed compared with those who had not been infected was quite a surprise." But the researchers do not know whether the changes are reversible or truly matter for health and wellbeing. "We need to bear in mind that the brain is really plastic - by that we mean it can heal itself - so there is a really good chance that, over time, the harmful effects of infection will ease," Prof Douaud said. The most significant loss of grey matter was in the olfactory areas - but it is unclear whether the virus directly attacks this region or cells simply die off through lack of use after people with Covid lose their sense of smell. UK Biobank chief scientist Prof Naomi Allen said: "It opens up all sorts of questions that other researchers can follow up about the effect of coronavirus infection on cognitive function, on brain fog and on other areas of the brain - and to really focus research on how best to mitigate that." Read full story Source: BBC News, 8 March 2022 -
News Article
Oral drug for spinal muscular atrophy to be available on NHS in England
Patient Safety Learning posted a news article in News
The NHS is to introduce a revolutionary new treatment to tackle the leading genetic cause of death among babies and young children. About 1,500 patients in England with certain types of spinal muscular atrophy (SMA) are expected to benefit from risdiplam, after a recommendation from the health watchdog. The drug, also called Evrysdi and made by Roche, is a syrup that can be taken at home and is the first non-injectable treatment for the condition. SMA is a progressive neuromuscular condition affecting the nerves in the spinal cord controlling movement and can cause paralysis, muscle weakness and progressive loss of mobility. The NHS England chief executive, Amanda Pritchard, said: “In the last three years the NHS has revolutionised care for people with SMA, by securing access to a trio of innovative treatments – Spinraza, Zolgensma and now risdiplam – where three years ago clinicians had no effective medicines at all. “Spinal muscular atrophy is a cruel disease and the leading genetic cause of death among babies and young children, which is why NHS England has been determined to make these treatments available to people as soon as possible to help transform the lives of patients and their families.” Meindert Boysen, the deputy chief executive of NICE, said the watchdog was pleased to recommend a “convenient oral treatment for people with SMA that can be administered at home”. He said: “This will not only be less burdensome, and therefore have a positive impact on the lives of both people with SMA and their caregivers, but it will also reduce the treatment administration requirements for the NHS. “In practical terms, the availability of an oral drug should lead to greater adherence to treatment, along with giving access to a treatment to those who aren’t able to have other currently recommended options.” Read full story Source: The Guardian, 19 November 2021- Posted
-
- Medication
- Patient
-
(and 2 more)
Tagged with:
-
Content ArticleEpilepsy12 was announced as the winner of the 2018 Richard Driscoll Memorial Award for outstanding patient involvement in clinical audit at the annual Healthcare Quality Improvement Partnership (HQIP) AGM in London. The submission from the Royal College of Paediatrics and Child Health (RCPCH) demonstrated Epilepsy12’s overarching goal to improve NHS healthcare services for children and young people with seizures and epilepsy.
- Posted
-
- Patient
- Paediatrics
- (and 9 more)
-
Content ArticleA team of ward nurses from Merseyside took part in the 2018–19 cohort of the Innovation Agency's coaching for culture programme. The team, led by ward manager Sharon Mcloughlin, were all from the Dott Ward at The Walton Centre NHS Foundation Trust, a specialist trust in north Liverpool dedicated to providing comprehensive neurology, neurosurgery, spinal and pain management services.
- Posted
-
- Treatment
- Medicine - Clinic neurophysiology
- (and 10 more)